The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Pharmacogenetics of human cytosolic sulfotransferases
Abstract
Cytosolic sulfotransferases (SULTs) are phase II detoxification enzymes that are involved in the biotransformation of a wide variety of structurally diverse endo- and xenobiotics, including many therapeutic agents and endogenous steroids. Single-nucleotide polymorphisms (SNPs) in SULTs have functional consequences on the translated protein. For the most part, these SNPs are fairly uncommon in the population, but some, most notably for SULT isoform 1A1, are commonly found and have been associated with cancer risk for a variety of tumor sites and also with response to therapeutic agents. SNPs in the hydroxysteroid sulfotransferase, SULT2A1, have been identified in African-American subjects and influence the ratio of plasma DHEA:DHEA-S. This modification could potentially influence cancer risk in steroidogenic tissues. SNPs in many SULTs are ethnically distributed, another factor that could influence SULT pharmacogenetics. Finally, genetic variation has also been identified in 3'-phosphoadenoside 5'-phosphosulfate synthetase (PAPPS), the enzymes responsible for producing the obligatory cosubstrate for all sulfotransferases. Taken together, this variability could substantially influence the disposition of drugs metabolized by SULTs. Elucidation of the basis and effect of variability in sulfation could greatly impact individualized therapy in the future.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“African-Americans have a high rate of polymorphisms in SULT2A1 apparently influencing plasma ratios of DHEA: DHEAS, which may correlate with the risk of prostatic and other cancers (603).”
From The Molecular Biology, Biochemistry, and Physiology of Human Steroidogenesis and Its Disorders (2011) · cites this paper as [603]
Citations
Cites
Effects of Tamoxifen on Bone Mineral Density in Postmenopausal Women with Breast Cancer
Love, R. R., Mazess, R. B., Barden, H. S., Epstein, S., Newcomb, P. A., Jordan, V. C., Carbone, P. P., & DeMets, D. L. (1992) · New England Journal of Medicine · doi:10.1056/nejm199203263261302 · Cited by 1,129 · cited 1×
“Tamoxifen has been the gold standard of endocrine therapy for breast cancer since the 1970s (1985; 1986; Mariotto et al., 2002) and its use has contributed significantly to the decline in breast cancer mortality (Love et al., 1992).”
BackgroundSulfotransferases in the bioactivation of xenobiotics
Glatt, H. (2000) · Chemico-Biological Interactions · doi:10.1016/s0009-2797(00)00202-7 · Cited by 354 · cited 1×
“To date, at least 11 different SULT enzymes have been identified (reviewed in Glatt, 2000).”
BackgroundThe effects of oral dehydroepiandrosterone on endocrine-metabolic parameters in postmenopausal women
MORTOLA, J. F., & YEN, S. S. C. (1990) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-71-3-696 · Cited by 311
Raftogianis, R. B., Wood, T. C., Otterness, D. M., Van Loon, J. A., & Weinshilboum, R. M. (1997) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1997.7466 · Cited by 305 · cited 1×
“These SNPs were in linkage disequilibrium with each other and with an SNP at 638, which is responsible for an aminoacid change from arginine to histidine at residue 213 (Raftogianis et al., 1997; Ozawa et al., 1998).”
BackgroundTyrosine Sulfation and the Secretory Pathway
Huttner, W. B. (1988) · Annual Review of Physiology · doi:10.1146/annurev.ph.50.030188.002051 · Cited by 263 · cited 1×
“SULTs involved in Phase II biotransformation of endoand xenobiotics are cytosolic, although there are membrane bound SULTs that are responsible for catalysing the sulfation of protein tyrosyl residues and polysaccharides (Huttner, 1988; Hashimoto and Hirschberg, 1992).”
BackgroundGenotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients
Wegman, P., Vainikka, L., Stål, O., Nordenskjöld, B., Skoog, L., Rutqvist, L.-E., & Wingren, S. (2005) · Breast Cancer Research · doi:10.1186/bcr993 · Cited by 243 · cited 1×
“A subsequent study in the context of a clinical trial also indicated the same trend of better overall survival associated with the SULT1A1*1 allele (Wegman et al., 2005) in patients treated with tamoxifen.”
ResultAdjuvant Chemotherapy for Breast Cancer
BLOMQVIST, C. P. (1985) · JAMA · doi:10.1001/jama.1985.03360240073038 · Cited by 237
Pharmacogenetics of Sulfotransferase
Nagata, K., & Yamazoe, Y. (2000) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.40.1.159 · Cited by 215 · cited 1×
“SULT pharmacogenetics have been the subject of two recent reviews (Nagata and Yamazoe, 2000; Glatt and Meinl, 2004).”
BackgroundKhetawat, G., Faraday, N., Nealen, M. L., Vijayan, K. V., Bolton, E., Noga, S. J., & Bray, P. F. (2000) · Blood · doi:10.1182/blood.v95.7.2289 · Cited by 210
Parker, C. R. (1999) · Steroids · doi:10.1016/s0039-128x(99)00046-x · Cited by 201 · cited 1×
“Humans synthesize large amounts of DHEA-sulfate during fetal development and after adrenarche (Parker, 1999).”
Background
Research works printed but not linked: 2
- Falany CN, Wheeler J, Oh TS, Falany JL . (1994b). J Steroid Biochem Mol Biol 48: 369–375. · DOI · Paper page
- Wilborn T, Lang N, Smith M, Meleth S, Falany C . (2005). J Steroid Biochem Mol Biol, in press.
Cited by
The Molecular Biology, Biochemistry, and Physiology of Human Steroidogenesis and Its Disorders
Miller, W. L., & Auchus, R. J. (2011) · Endocrine Reviews · doi:10.1210/er.2010-0013 · Cited by 2,458
Nebert, D. W., & Dalton, T. P. (2006) · Nature Reviews Cancer · doi:10.1038/nrc2015 · Cited by 958
Heger, M., van Golen, R. F., Broekgaarden, M., & Michel, M. C. (2014) · Pharmacological Reviews · doi:10.1124/pr.110.004044 · Cited by 576
“intestinal epithelial cells contain a host of cytosolic SULTs, among which are members of the phenol SULT subfamily (SULT1) that are responsible for catalyzing the transfer of a sulfonyl group from 39-phosphoadenosine 59-phosphosulfate to a wide variety of phenolic xenobiotics (Eisenhofer et al., 1999; Nowell and Fala…”
BackgroundThe role of metabolism (and the microbiome) in defining the clinical efficacy of dietary flavonoids
Cassidy, A., & Minihane, A.-M. (2017) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.116.136051 · Cited by 508
“with altered drugs responses and sex-steroid concentrations (18, 43).”
BackgroundCaraco, Y., Blotnick, S., & Muszkat, M. (2008) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100316 · Cited by 360
Metadata
- Authors
- Nowell, S., & Falany, C. N.
- Affiliations
- University of Arkansas for Medical Sciences (US)
- University of Alabama at Birmingham (US)
- Corresponding author
- Nowell, S
- Falany, C N
- Venue
- Oncogene
- Published
- 2006-03-13
- Volume
- 25
- Issue
- 11
- Pages
- 1673-1678
- ISSN
- 0950-9232 (ISSN-L)
- 1476-5594
- OpenAlex
- W2058380077
- Semantic Scholar
- 4a231f71813b6ba42e0f4860c32817dcb237908f
- Cited by
- 158
- References
- 49
- Citations by year
- 2026: 7 · 2025: 2 · 2024: 3 · 2023: 6 · 2022: 6 · 2021: 6 · 2020: 5 · 2019: 2 · 2018: 5 · 2017: 9 · 2016: 11 · 2015: 4 · 2014: 9 · 2013: 8 · 2012: 15
- FWCI
- 1.38
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Oncogene (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Glutathione Transferases and Polymorphisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Keywords
- cytosolic sulfotransferases, SULT1A1, SULT2A1, hydroxysteroid sulfotransferase, single nucleotide polymorphisms, genetic variation, cancer risk, drug metabolism, sulfation, 3'-phosphoadenosine 5'-phosphosulfate, personalized treatment, phase II enzymes
- MeSH terms
- Antineoplastic Agents, Black or African American, Ethnicity, Humans, Isoenzymes, Neoplasms, Pharmacogenetics, Sulfotransferases, Arylsulfotransferase, Xenobiotics, Polymorphism, Single Nucleotide
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pharmacogenetics of human cytosolic sulfotransferases. https://app.cochat.ai/papers/10.1038/sj.onc.1209376
- The paper
- Nowell, S., & Falany, C. N. (2006). Pharmacogenetics of human cytosolic sulfotransferases. Oncogene. https://doi.org/10.1038/sj.onc.1209376
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.